Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 3e5ed294-188e-d226-e063-6394a90a5326

SIMPONI ARIA

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-09-09
Captured
2026-09-09T23:37:44.904352+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA ( 5.1 ). Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ). Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member ( 5.2 ). SERIOUS INFECTIONS Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue SIMPONI ARIA if a patient develops a serious infection. Reported infections with TNF blockers, of which SIMPONI ARIA is a member, include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before SIMPONI ARIA use and during therapy. Initiate treatment for latent tuberculosis prior to SIMPONI ARIA use. Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. Consider the risks and benefits of treatment with SIMPONI ARIA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMPONI ARIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, of which SIMPONI ARIA is a member [see Warnings and Precautions (5.2) ] .

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
Full extracted label fields
application numbers
  1. BLA125433
boxed warning exact
  1. WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA ( 5.1 ). Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ). Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member ( 5.2 ). SERIOUS INFECTIONS Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue SIMPONI ARIA if a patient develops a serious infection. Reported infections with TNF blockers, of which SIMPONI ARIA is a member, include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before SIMPONI ARIA use and during therapy. Initiate treatment for latent tuberculosis prior to SIMPONI ARIA use. Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. Consider the risks and benefits of treatment with SIMPONI ARIA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMPONI ARIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, of which SIMPONI ARIA is a member [see Warnings and Precautions (5.2) ] .
brand names
  1. SIMPONI ARIA
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e260a47-55af-4c92-8d88-a86ccc767fff
generic names
  1. GOLIMUMAB
id
3e5ed294-188e-d226-e063-6394a90a5326
indications and usage exact
  1. 1 INDICATIONS AND USAGE SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Janssen Biotech, Inc.
    matched search terms
    1. tumor
    package ndcs
    1. 57894-350-01
    2. 57894-350-89
    product ndcs
    1. 57894-350
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
      record type
      complete_spl_indications_section_candidate
      routes
      1. INTRAVENOUS
      rxcuis
      1. 1431642
      2. 1431647
      source batch
      file
      /private/tmp/cancer-full-research/indications/raw/labels-00200.json
      meta
      disclaimer
      Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
      last updated
      2026-09-09
      results
      limit
      100
      skip
      200
      total
      830
      sha256
      d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
      url
      https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=200&sort=id%3Aasc
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
      spl effective date
      2025-09-09
      spl effective time
      20250909
      spl set id
      9e260a47-55af-4c92-8d88-a86ccc767fff
      spl version
      28
      substance names
      1. GOLIMUMAB
      uniis
      1. 91X1KLU43E
      verification flags
      1. oncology_keyword_candidate_not_clinically_classified
      2. spl_text_not_verified_identical_to_latest_approved_label
      3. individual_indications_not_split_or_reconciled
      Drugs@FDA application source records
      1. application number
        BLA125433
        payload
        all indexed label documents
        1. Appl No
          125433
          Application Docs Date
          2013-07-22 00:00:00
          Application Docs ID
          18915
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          1
          Submission Type
          ORIG
        2. Appl No
          125433
          Application Docs Date
          2014-02-12 00:00:00
          Application Docs ID
          18916
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          5
          Submission Type
          SUPPL
        3. Appl No
          125433
          Application Docs Date
          2014-02-06 00:00:00
          Application Docs ID
          39967
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          2
          Submission Type
          SUPPL
        4. Appl No
          125433
          Application Docs Date
          2015-08-06 00:00:00
          Application Docs ID
          39968
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          14
          Submission Type
          SUPPL
        5. Appl No
          125433
          Application Docs Date
          2016-01-12 00:00:00
          Application Docs ID
          39969
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          15
          Submission Type
          SUPPL
        6. Appl No
          125433
          Application Docs Date
          2016-05-03 00:00:00
          Application Docs ID
          39970
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          16
          Submission Type
          SUPPL
        7. Appl No
          125433
          Application Docs Date
          2016-02-23 00:00:00
          Application Docs ID
          39971
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          17
          Submission Type
          SUPPL
        8. Appl No
          125433
          Application Docs Date
          2016-08-19 00:00:00
          Application Docs ID
          45105
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          18
          Submission Type
          SUPPL
        9. Appl No
          125433
          Application Docs Date
          2017-01-30 00:00:00
          Application Docs ID
          47063
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          19
          Submission Type
          SUPPL
        10. Appl No
          125433
          Application Docs Date
          2017-10-24 00:00:00
          Application Docs ID
          50168
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          20
          Submission Type
          SUPPL
        11. Appl No
          125433
          Application Docs Date
          2017-10-24 00:00:00
          Application Docs ID
          50169
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          21
          Submission Type
          SUPPL
        12. Appl No
          125433
          Application Docs Date
          2018-02-09 00:00:00
          Application Docs ID
          52533
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          24
          Submission Type
          SUPPL
        all submission records
        1. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          36
          Submission Status
          AP
          Submission Status Date
          2025-04-18 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        2. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          32
          Submission Status
          AP
          Submission Status Date
          2021-02-01 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        3. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          31
          Submission Status
          AP
          Submission Status Date
          2020-09-29 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        4. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          30
          Submission Status
          AP
          Submission Status Date
          2020-09-29 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        5. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          28
          Submission Status
          AP
          Submission Status Date
          2019-09-24 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        6. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          24
          Submission Status
          AP
          Submission Status Date
          2018-02-09 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        7. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          21
          Submission Status
          AP
          Submission Status Date
          2017-10-20 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        8. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          20
          Submission Status
          AP
          Submission Status Date
          2017-10-20 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        9. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          19
          Submission Status
          AP
          Submission Status Date
          2017-01-30 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        10. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          18
          Submission Status
          AP
          Submission Status Date
          2016-08-19 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        11. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          17
          Submission Status
          AP
          Submission Status Date
          2016-02-22 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        12. Appl No
          125433
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          16
          Submission Status
          AP
          Submission Status Date
          2016-04-26 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        application number
        BLA125433
        approval interpretation
        Application linkage and approved submission are not indication-level current approval verification
        current indication status
        not_reconciled
        has approved submission record
        true
        latest approved submission date
        2025-04-18
        latest label selection rule
        max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
        latest posted label documents
        1. Appl No
          125433
          Application Docs Date
          2025-04-25 00:00:00
          Application Docs ID
          82003
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          36
          Submission Type
          SUPPL
        official application record
        Appl No
        125433
        Appl Public Notes
        Appl Type
        BLA
        Sponsor Name
        JANSSEN BIOTECH
        openfda application present
        true
        products
        1. Active Ingredient
          GOLIMUMAB
          Appl No
          125433
          Drug Name
          SIMPONI ARIA
          Form
          INJECTABLE; INJECTION
          Product No
          001
          Reference Drug
          0
          Reference Standard
          Strength
          50MG/4ML
          marketing status
          1. Prescription

      Source passages and status connections

      Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

      Passage 1 · positive indication candidate
      application numbers
      1. BLA125433
      brand names
      1. SIMPONI ARIA
      classification reasons
      1. explicit_positive_indication_predicate
      2. tumor_or_malignant_hematology_words_in_positive_statement
      clinical review status
      pending
      content role
      positive_indication_candidate
      context span
      end
      504
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIM
      label id
      3e5ed294-188e-d226-e063-6394a90a5326
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
      start
      0
      current approval status
      not_reconciled
      duplicate text group
      dup-aca09762253800b5390e
      extraction review status
      automated_candidate_pending_source_review
      generic names
      1. GOLIMUMAB
      id
      ind-span-8b11e50aa1f92b828f02
      label id
      3e5ed294-188e-d226-e063-6394a90a5326
      positive predicate support span
      end
      87
      end exclusive
      true
      exact text
      is a tumor necrosis factor (TNF) blocker indicated
      label id
      3e5ed294-188e-d226-e063-6394a90a5326
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
      start
      37
      qualifier mentions
      1. context exact
        crosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA
        kind
        age
        polarity
        not_inferred
        span
        end
        124
        end exclusive
        true
        exact text
        Adult patients
        label id
        3e5ed294-188e-d226-e063-6394a90a5326
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
        start
        110
      2. context exact
        rexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 )
        kind
        age
        polarity
        not_inferred
        span
        end
        286
        end exclusive
        true
        exact text
        2 years of age
        label id
        3e5ed294-188e-d226-e063-6394a90a5326
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
        start
        272
      3. context exact
        verely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of
        kind
        biomarker
        polarity
        not_inferred
        span
        end
        222
        end exclusive
        true
        exact text
        methotrexate ( 1
        label id
        3e5ed294-188e-d226-e063-6394a90a5326
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
        start
        206
      4. context exact
        ith moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of
        kind
        regimen
        polarity
        not_inferred
        span
        end
        222
        end exclusive
        true
        exact text
        in combination with methotrexate ( 1
        label id
        3e5ed294-188e-d226-e063-6394a90a5326
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
        start
        186
      regulatory links
        schema version
        0.1.0
        source batch sha256
        d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
        source defined aliases
          source span
          end
          304
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 )
          label id
          3e5ed294-188e-d226-e063-6394a90a5326
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
          start
          0
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
          spl effective date
          2025-09-09
          spl set id
          9e260a47-55af-4c92-8d88-a86ccc767fff
          spl version
          28
          structured fields status
          not_extracted_no_values_inferred_from_mentions
          structured indication
          age
          Source null
          approval pathway
          Source null
          biomarker and test
          Source null
          disease stage
          Source null
          limitations
          Source null
          line
          Source null
          prior therapy
          Source null
          regimen
          Source null
          tumor histology
          Source null
          use intent
          tumor_directed_candidate
          Passage 2 · positive indication candidate
          application numbers
          1. BLA125433
          brand names
          1. SIMPONI ARIA
          classification reasons
          1. inherited_predicate_from_same_label_section_requires_review
          2. no_tumor_directed_keyword_in_positive_statement
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          670
          end exclusive
          true
          exact text
          of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psori
          label id
          3e5ed294-188e-d226-e063-6394a90a5326
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
          start
          105
          current approval status
          not_reconciled
          duplicate text group
          dup-77936799685b2593df7e
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. GOLIMUMAB
          id
          ind-span-b12306438de024f8e168
          label id
          3e5ed294-188e-d226-e063-6394a90a5326
          positive predicate support span
          end
          87
          end exclusive
          true
          exact text
          is a tumor necrosis factor (TNF) blocker indicated
          label id
          3e5ed294-188e-d226-e063-6394a90a5326
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
          start
          37
          qualifier mentions
          1. context exact
            Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active poly
            kind
            age
            polarity
            not_inferred
            span
            end
            319
            end exclusive
            true
            exact text
            Adult patients
            label id
            3e5ed294-188e-d226-e063-6394a90a5326
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
            start
            305
          2. context exact
            yarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )
            kind
            age
            polarity
            not_inferred
            span
            end
            452
            end exclusive
            true
            exact text
            2 years of age
            label id
            3e5ed294-188e-d226-e063-6394a90a5326
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
            start
            438
          regulatory links
            schema version
            0.1.0
            source batch sha256
            d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
            source defined aliases
              source span
              end
              470
              end exclusive
              true
              exact text
              Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )
              label id
              3e5ed294-188e-d226-e063-6394a90a5326
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
              start
              305
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
              spl effective date
              2025-09-09
              spl set id
              9e260a47-55af-4c92-8d88-a86ccc767fff
              spl version
              28
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              non_oncology_or_unclear_candidate
              Passage 3 · positive indication candidate
              application numbers
              1. BLA125433
              brand names
              1. SIMPONI ARIA
              classification reasons
              1. explicit_positive_indication_predicate
              2. no_tumor_directed_keyword_in_positive_statement
              clinical review status
              pending
              content role
              positive_indication_candidate
              context span
              end
              860
              end exclusive
              true
              exact text
              2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated
              label id
              3e5ed294-188e-d226-e063-6394a90a5326
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
              start
              271
              current approval status
              not_reconciled
              duplicate text group
              dup-f9525d8951eabb1299a7
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. GOLIMUMAB
              id
              ind-span-ba214d3ed7629af73618
              label id
              3e5ed294-188e-d226-e063-6394a90a5326
              positive predicate support span
              end
              567
              end exclusive
              true
              exact text
              is indicated
              label id
              3e5ed294-188e-d226-e063-6394a90a5326
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
              start
              555
              qualifier mentions
              1. context exact
                with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
                kind
                age
                polarity
                not_inferred
                span
                end
                603
                end exclusive
                true
                exact text
                adult patients
                label id
                3e5ed294-188e-d226-e063-6394a90a5326
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                start
                589
              2. context exact
                Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with mode
                kind
                biomarker
                polarity
                not_inferred
                span
                end
                553
                end exclusive
                true
                exact text
                methotrexate (MTX)
                label id
                3e5ed294-188e-d226-e063-6394a90a5326
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                start
                535
              3. context exact
                1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
                kind
                regimen
                polarity
                not_inferred
                span
                end
                659
                end exclusive
                true
                exact text
                in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis
                label id
                3e5ed294-188e-d226-e063-6394a90a5326
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                start
                515
              regulatory links
                schema version
                0.1.0
                source batch sha256
                d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                source defined aliases
                  source span
                  end
                  660
                  end exclusive
                  true
                  exact text
                  1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
                  label id
                  3e5ed294-188e-d226-e063-6394a90a5326
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                  start
                  471
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
                  spl effective date
                  2025-09-09
                  spl set id
                  9e260a47-55af-4c92-8d88-a86ccc767fff
                  spl version
                  28
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  non_oncology_or_unclear_candidate
                  Passage 4 · positive indication candidate
                  application numbers
                  1. BLA125433
                  brand names
                  1. SIMPONI ARIA
                  classification reasons
                  1. explicit_positive_indication_predicate
                  2. no_tumor_directed_keyword_in_positive_statement
                  clinical review status
                  pending
                  content role
                  positive_indication_candidate
                  context span
                  end
                  1002
                  end exclusive
                  true
                  exact text
                  r ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA i
                  label id
                  3e5ed294-188e-d226-e063-6394a90a5326
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                  start
                  461
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-663e1f286e32e9a6f4e8
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. GOLIMUMAB
                  id
                  ind-span-0c681b310ba46678470e
                  label id
                  3e5ed294-188e-d226-e063-6394a90a5326
                  positive predicate support span
                  end
                  716
                  end exclusive
                  true
                  exact text
                  is indicated
                  label id
                  3e5ed294-188e-d226-e063-6394a90a5326
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                  start
                  704
                  qualifier mentions
                  1. context exact
                    for the treatment of active psoriatic arthritis in patients 2 years of age and older.
                    kind
                    age
                    polarity
                    not_inferred
                    span
                    end
                    791
                    end exclusive
                    true
                    exact text
                    2 years of age
                    label id
                    3e5ed294-188e-d226-e063-6394a90a5326
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                    start
                    777
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                    source defined aliases
                      source span
                      end
                      802
                      end exclusive
                      true
                      exact text
                      1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older.
                      label id
                      3e5ed294-188e-d226-e063-6394a90a5326
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                      start
                      661
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
                      spl effective date
                      2025-09-09
                      spl set id
                      9e260a47-55af-4c92-8d88-a86ccc767fff
                      spl version
                      28
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      non_oncology_or_unclear_candidate
                      Passage 5 · positive indication candidate
                      application numbers
                      1. BLA125433
                      brand names
                      1. SIMPONI ARIA
                      classification reasons
                      1. explicit_positive_indication_predicate
                      2. no_tumor_directed_keyword_in_positive_statement
                      clinical review status
                      pending
                      content role
                      positive_indication_candidate
                      context span
                      end
                      1130
                      end exclusive
                      true
                      exact text
                      with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
                      label id
                      3e5ed294-188e-d226-e063-6394a90a5326
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                      start
                      603
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-6829df962c00db0bf644
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. GOLIMUMAB
                      id
                      ind-span-f664ba965b744449e757
                      label id
                      3e5ed294-188e-d226-e063-6394a90a5326
                      positive predicate support span
                      end
                      860
                      end exclusive
                      true
                      exact text
                      is indicated
                      label id
                      3e5ed294-188e-d226-e063-6394a90a5326
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                      start
                      848
                      qualifier mentions
                      1. context exact
                        dylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis.
                        kind
                        age
                        polarity
                        not_inferred
                        span
                        end
                        896
                        end exclusive
                        true
                        exact text
                        adult patients
                        label id
                        3e5ed294-188e-d226-e063-6394a90a5326
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                        start
                        882
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                        source defined aliases
                          source span
                          end
                          932
                          end exclusive
                          true
                          exact text
                          1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis.
                          label id
                          3e5ed294-188e-d226-e063-6394a90a5326
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                          start
                          803
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
                          spl effective date
                          2025-09-09
                          spl set id
                          9e260a47-55af-4c92-8d88-a86ccc767fff
                          spl version
                          28
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          non_oncology_or_unclear_candidate
                          Passage 6 · positive indication candidate
                          application numbers
                          1. BLA125433
                          brand names
                          1. SIMPONI ARIA
                          classification reasons
                          1. explicit_positive_indication_predicate
                          2. no_tumor_directed_keyword_in_positive_statement
                          clinical review status
                          pending
                          content role
                          positive_indication_candidate
                          context span
                          end
                          1130
                          end exclusive
                          true
                          exact text
                          t of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
                          label id
                          3e5ed294-188e-d226-e063-6394a90a5326
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                          start
                          733
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-355ac2c9e1a06ed421f7
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. GOLIMUMAB
                          id
                          ind-span-d3d808d8afcb5869506f
                          label id
                          3e5ed294-188e-d226-e063-6394a90a5326
                          positive predicate support span
                          end
                          1013
                          end exclusive
                          true
                          exact text
                          is indicated
                          label id
                          3e5ed294-188e-d226-e063-6394a90a5326
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                          start
                          1001
                          qualifier mentions
                          1. context exact
                            yarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
                            kind
                            age
                            polarity
                            not_inferred
                            span
                            end
                            1119
                            end exclusive
                            true
                            exact text
                            2 years of age
                            label id
                            3e5ed294-188e-d226-e063-6394a90a5326
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                            start
                            1105
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                            source defined aliases
                              source span
                              end
                              1130
                              end exclusive
                              true
                              exact text
                              1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
                              label id
                              3e5ed294-188e-d226-e063-6394a90a5326
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              da6547c81288691053243a67ad6e5474b41c78abef13d3755afa9a7ecb198148
                              start
                              933
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%223e5ed294-188e-d226-e063-6394a90a5326%22
                              spl effective date
                              2025-09-09
                              spl set id
                              9e260a47-55af-4c92-8d88-a86ccc767fff
                              spl version
                              28
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              non_oncology_or_unclear_candidate

                              Preserved source evidence · Not medical advice